China Medical System Holdings Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Kong Lam

Chief Executive Officer (CEO)

CN¥5.4m

Compensación total

Porcentaje del salario del CEO	93.5%
Permanencia del CEO	17.9yrs
Participación del CEO	48.3%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	12.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kong Lam en comparación con los beneficios de China Medical System Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	CN¥1b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥5m	CN¥5m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥3b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥6m	CN¥5m	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥3b
Dec 31 2021	CN¥5m	CN¥4m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥3b
Dec 31 2020	CN¥4m	CN¥4m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥2b
Mar 31 2020	n/a	n/a	CN¥2b
Dec 31 2019	CN¥4m	CN¥3m	CN¥2b
Sep 30 2019	n/a	n/a	CN¥2b
Jun 30 2019	n/a	n/a	CN¥2b
Mar 31 2019	n/a	n/a	CN¥2b
Dec 31 2018	CN¥3m	CN¥3m	CN¥2b
Sep 30 2018	n/a	n/a	CN¥2b
Jun 30 2018	n/a	n/a	CN¥2b
Mar 31 2018	n/a	n/a	CN¥2b
Dec 31 2017	CN¥782k	CN¥610k	CN¥2b

Compensación vs. Mercado: La compensación total de Kong($USD751.23K) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD487.65K).

Compensación vs. Ingresos: La compensación de Kong ha sido consistente con los resultados de la empresa en el último año.

CEO

Kong Lam (59 yo)

17.9yrs

Permanencia

CN¥5,443,000

Compensación

Dr. Lam Kong founded and serves as the Chairman and Chief Executive Officer of China Medical System Holdings Limited and has been its Executive Director since December 18, 2006. Mr. Lam serves as President...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kong Lam	Founder	17.9yrs	CN¥5.44m	48.32% HK$ 8.6b
Yanling Chen	CFO, VP & Executive Director	17.9yrs	CN¥4.43m	0.30% HK$ 53.3m
Hongbing Chen	COO, VP	17.9yrs	CN¥5.04m	2.91% HK$ 516.4m
Chong Shun Leung	Independent Non-Executive Director	6.9yrs	CN¥323.00k	sin datos
Ying Luo	Independent Non-Executive Director	4.7yrs	CN¥323.00k	sin datos
Ching Fung	Independent Non-Executive Director	3.1yrs	CN¥323.00k	sin datos

12.4yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 867 son experimentados ( 12.4 años antigüedad media).

China Medical System Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Founder recently bought HK$3.6m worth of stock

China Medical System Holdings Limited Announces Re-Designation of Directors

Founder recently bought HK$6.8m worth of stock

China Medical System Holdings Limited, Annual General Meeting, May 09, 2024

Founder recently bought HK$23m worth of stock

Recent updates

China Medical System Holdings Limited Announces New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved in Hong Kong

Insufficient new directors

Investor sentiment improves as stock rises 20%

China Medical System Holdings Limited Announces New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China

Founder recently bought HK$3.6m worth of stock

First half dividend of HK$0.16 announced

First half 2024 earnings released: EPS: CN¥0.37 (vs CN¥0.78 in 1H 2023)

China Medical System Holdings Limited Announces Re-Designation of Directors

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on About 9 September 2024

China Medical System Holdings Limited Announces NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China

China Medical System Holdings Limited to Report First Half, 2024 Results on Aug 15, 2024

China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China

China Medical System Holdings Limited Announces Approval of Lumeblue® by NMPA for Enhanced Colorectal Lesion Detection

Now 20% undervalued after recent price drop

Founder recently bought HK$6.8m worth of stock

Now 20% undervalued after recent price drop

China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023

Now 21% undervalued after recent price drop

China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 40%

China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024

Final dividend of HK$0.086 announced

China Medical System Holdings Limited, Annual General Meeting, May 09, 2024

Now 38% undervalued after recent price drop

Full year 2023 earnings released: EPS: CN¥0.98 (vs CN¥1.33 in FY 2022)

China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024

China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China

China Medical System Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China

China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application (Nda) for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China

Upcoming dividend of HK$0.34 per share at 5.1% yield

First half 2023 earnings released: EPS: CN¥0.78 (vs CN¥0.73 in 1H 2022)

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 20, 2023

China Medical System Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

China Medical System Holdings Limited Receives Approval from National Medical Products Administration of China for New Drug Application of Diazepam Nasal Spray

National Medical Products Administration of China Approves China Medical System Holdings's New Drug Application of Tildrakizumab Injection under the Brand Name of ILUMETRI

Upcoming dividend of HK$0.27 per share at 4.5% yield

Full year 2022 earnings released: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021)

China Medical System Holdings Limited Announces New Drug Application of Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets

China Medical System Holdings Limited Announces its Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Obtains Positive Results for its Phase III Clinical Trial in China

Investor sentiment improved over the past week

Upcoming dividend of HK$0.34 per share

First half 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.66 in 1H 2021)

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 15 September 2022

China Medical System Holdings Limited to Report First Half, 2022 Results on Aug 22, 2022

China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.28 per share

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

China Medical System Holdings Limited to Report Fiscal Year 2021 Results on Mar 15, 2022

China Medical System Holdings Limited Announces New Drug Application of Methotrexate Injection, Pre-Filled Syringe Accepted in China

Independent Non-Executive Director Chi Keung Wu has left the company

China Medical System Holdings Limited Establishes A New Programme with XF-73 Targeting the Prevention and Treatment of Superficial Skin Infections Caused by Bacteria

Upcoming dividend of HK$0.32 per share

First half 2021 earnings released: EPS CN¥0.66 (vs CN¥0.52 in 1H 2020)

National Medical Products Grants Approval to China Medical System Holdings Limited's Methotrexate Injection, Pre-Filled Syringe

China Medical System Holdings Limited Receives Approval for Innovative Patented Drug Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets

China Medical System Holdings Limited Announces That the Group's Innovative Drug Tildrakizumab Solution for Injection Obtained Positive Results of Its Phase Clinical Trial in China

China Medical System Holdings Limited Announces New Drug Application of Diazepam Nasal Spray Accepted in China

China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2020

Upcoming dividend of HK$0.24 per share

Full year 2020 earnings released: EPS CN¥1.02 (vs CN¥0.79 in FY 2019)

China Medical System Holdings Limited Recommends a Final Dividend for the Year Ended 31 December 2020, Payable About 10 May 2021

Full year 2020 earnings released

Investor sentiment improved over the past week

China Medical System Holdings Limited to Report Fiscal Year 2020 Results on Mar 16, 2021

Investor sentiment deteriorated over the past week

New 90-day high: HK$13.58